<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080621</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-2618-01-008</org_study_id>
    <nct_id>NCT05080621</nct_id>
  </id_info>
  <brief_title>Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)</brief_title>
  <official_title>A Phase 1b/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label Phase 1b/2 study of ripretinib in combination with binimetinib in&#xD;
      patients with gastrointestinal stromal tumor (GIST). There will be 2 distinct parts in this&#xD;
      study: Dose Escalation (Phase 1) and Expansion (Phase 2).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2027</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability of oral ripretinib in combination with binimetinib: incidence of adverse events</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Adverse events [TEAEs, SAEs, AESIs], dose reduction, dose interruption, or discontinuation, vital signs (heart rate [beats/min], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of the Maximum Tolerated Dose and the Recommended Phase 2 Dose</measure>
    <time_frame>Approximately 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion Phase Only: Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the time to maximum observed concentration (tmax) profile of oral ripretinib in combination with binimetinib</measure>
    <time_frame>Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days</time_frame>
    <description>Measure Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the maximum observed concentration (Cmax) profile of oral ripretinib in combination with binimetinib</measure>
    <time_frame>Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days</time_frame>
    <description>Measure Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the minimum observed concentration (Cmin) profile of oral ripretinib in combination with binimetinib</measure>
    <time_frame>Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days</time_frame>
    <description>Measure Cmin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the area under the concentration-time curve (AUC) profile of oral ripretinib in combination with binimetinib</measure>
    <time_frame>Cycle 1 Day 1, and Cycle 1 Day15 (pre-dose and at multiple time points [up to 8 hours] post-dose). Each cycle is 28 days</time_frame>
    <description>Measure AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the objective response rate (ORR) of ripretinib in combination with binimetinib by modified RECIST (escalation phase only) and Choi criteria (escalation and expansion phases)</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure ORR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival (PFS) of ripretinib in combination with binimetinib</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure PFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the overall survival (OS) of ripretinib in combination with binimetinib</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the duration of response (DOR) of ripretinib in combination with binimetinib</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the clinical benefit rate (CBR) of ripretinib in combination with binimetinib</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure CBR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the time to response (TTR) of ripretinib in combination with binimetinib</measure>
    <time_frame>Approximately 36 months</time_frame>
    <description>Measure TTR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <arm_group>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalation Phase: Increasing doses of ripretinib in combination with increase doses of binimetinib in patients with advanced GIST who have progressed on at least imatinib or are intolerant to imatinib and are ripretinib naïve in repeated 28-day cycles.&#xD;
Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ripretinib in combination with binimetinib at the recommended Phase 2 dose (RP2D) in patients with advanced GIST who have progressed on imatinib or are intolerant to imatinib and are naïve.&#xD;
Participants may remain on treatment until disease progression, unacceptable toxicity, or withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ripretinib</intervention_name>
    <description>50 mg tablets</description>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
    <other_name>DCC-2618, QINLOCK</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>binimetinib</intervention_name>
    <description>15 mg tablets</description>
    <arm_group_label>Escalation</arm_group_label>
    <arm_group_label>Expansion</arm_group_label>
    <other_name>Mektovi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ≥18 years of age with advanced GIST (unresectable or metastatic).&#xD;
&#xD;
          2. Must have at least progressed on imatinib or have documented intolerance to imatinib.&#xD;
&#xD;
          3. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             (PS) of 0 or 1.&#xD;
&#xD;
          4. Patients must have a histologic diagnosis of GIST.&#xD;
&#xD;
          5. If a female of childbearing potential, must have a negative pregnancy test.&#xD;
&#xD;
          6. Adequate organ function and bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received prior anticancer therapy within 14 days or 5× the half-life whichever is&#xD;
             longer) prior to the first dose.&#xD;
&#xD;
          2. Ongoing or prior participation in the DCC-2618-03-002 study.&#xD;
&#xD;
          3. Prior therapy with ripretinib.&#xD;
&#xD;
          4. Prior therapy with MEK inhibitor.&#xD;
&#xD;
          5. History of certain ocular disorders.&#xD;
&#xD;
          6. History of clinically significant hepatobiliary disease.&#xD;
&#xD;
          7. Known active central nervous system metastases.&#xD;
&#xD;
          8. History or presence of clinically relevant cardiovascular abnormalities.&#xD;
&#xD;
          9. Systemic arterial or venous thrombotic or embolic events within 6 months of first&#xD;
             dose.&#xD;
&#xD;
         10. History of acute or chronic pancreatitis&#xD;
&#xD;
         11. History of chronic inflammatory bowel disease or Crohn's disease requiring&#xD;
             intervention within 12 months of first dose.&#xD;
&#xD;
         12. Gastrointestinal abnormalities including but not limited to:&#xD;
&#xD;
               -  inability to take oral medication,&#xD;
&#xD;
               -  malabsorption syndromes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>785-830-2100</phone>
    <email>clinicaltrials@deciphera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami - Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Jonathan Trent, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ping Chi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Neeta Somaiah, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Albiruni Razak, MB MRCPI</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West German Cancer Center - University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sebastian Bauer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>César Serrano, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

